| Literature DB >> 35565812 |
Sunil K Saini1,2, Arashdeep Singh3, Manisha Saini4, Marta Gonzalez-Freire5, Christiaan Leeuwenburgh2, Stephen D Anton2,6.
Abstract
Time-restricted eating (TRE), a popular form of intermittent fasting, has been demonstrated to provide multiple health benefits, including an extension of healthy lifespan in preclinical models. While the specific mechanisms remain elusive, emerging research indicates that one plausible mechanism through which TRE may confer health benefits is by influencing the expression of the epigenetic modulator circulatory miRNAs, which serve as intercellular communicators and are dysregulated in metabolic disorders, such as obesity. Therefore, the goal of this pilot study is to examine the effects of a 4-week TRE regimen on global circulatory miRNA from older (≥65 years) overweight participants. Pre- and post-TRE regimen serum samples from nine individuals who participated in the Time to Eat clinical trial (NCT03590847) and had a significant weight loss (2.6 kg, p < 0.01) were analyzed. The expressions of 2083 human miRNAs were quantified using HTG molecular whole transcriptome miRNA assay. In silico analyses were performed to determine the target genes and biological pathways associated with differentially expressed miRNAs to predict the metabolic effects of the TRE regimen. Fourteen miRNAs were differentially expressed pre- and post-TRE regimen. Specifically, downregulated miRNA targets suggested increased expression of transcripts, including PTEN, TSC1, and ULK1, and were related to cell growth and survival. Furthermore, the targets of downregulated miRNAs were associated with Ras signaling (cell growth and proliferation), mTOR signaling (cell growth and protein synthesis), insulin signaling (glucose uptake), and autophagy (cellular homeostasis and survival). In conclusion, the TRE regimen downregulated miRNA, which, in turn, could inhibit the pathways of cell growth and activate the pathways of cell survival and might promote healthy aging. Future mechanistic studies are required to understand the functional role of the miRNAs reported in this study.Entities:
Keywords: cell survival; diet; fat loss; intermittent fasting; weight loss
Mesh:
Substances:
Year: 2022 PMID: 35565812 PMCID: PMC9100641 DOI: 10.3390/nu14091843
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
List of differentially expressed miRNAs in participants post-TRE regimen.
| miRNA Name | log2 Fold Change | |
|---|---|---|
| miR-2467-3p | −0.41 | 0.002 |
| miR-4649-5p | −0.42 | 0.005 |
| miR-4513 | 0.40 | 0.015 |
| miR-3132 | −0.32 | 0.021 |
| miR-411-5p | 0.35 | 0.024 |
| miR-7162-3p | 0.31 | 0.027 |
| miR-301a-3p | −0.32 | 0.028 |
| miR-5682 | 0.36 | 0.028 |
| miR-19a-5p | −0.31 | 0.032 |
| miR-543 | −0.33 | 0.036 |
| miR-495-3p | −0.30 | 0.037 |
| miR-4761-3p | −0.28 | 0.038 |
| miR-623 | 0.29 | 0.044 |
| miR-4303 | 0.31 | 0.045 |
Figure 1Differentially expressed miRNAs between human subjects during the pre- and post-TRE regimen. Highlighted are the names of differentially expressed miRNAs with p < 0.05. Upregulated miRNAs are represented on the upper right quadrant (red dots) and downregulated miRNAs on the upper left quadrant (blue dots).
Associated biological pathways with miRNA targets: KEGG pathway.
| Name | Genes | Adjusted |
|---|---|---|
| ErbB_signaling_pathway | CAMK2G; MAPK10; CBLB; MAPK1; CBL; SOS2 | 0.002 |
| Ras_signaling_pathway | GRIN2A; RAB5B; MAPK10; FGF7; MAPK1; RALBP1; RASGRF2; SOS2 | 0.006 |
| mTOR_signaling_pathway | PTEN; TSC1; ULK2; LRP6; MAPK1; SOS2 | 0.006 |
| Insulin_signaling_pathway | TSC1; MAPK10; CBLB; MAPK1; CBL; SOS2 | 0.006 |
| Pathways_in_cancer | AR; PTEN; ARHGEF12; CAMK2G; MAPK10; FGF7; LRP6; MAPK1; CBL; RALBP1; SKP1; SOS2 | 0.006 |
| cAMP_signaling_pathway | GRIN2A; PDE3A; PDE4D; CAMK2G; MAPK10; MAPK1 | 0.014 |
| Autophagy | PTEN; TSC1; ULK2; MAPK10; MAPK1 | 0.014 |
| Regulation_of_actin_cytoskeleton | ENAH; ARHGEF12; ITGB5; FGF7; MAPK1; SOS2 | 0.014 |
| Proteoglycans_in_cancer | ARHGEF12; CAMK2G; ITGB5; MAPK1; CBL; SOS2 | 0.014 |
| Breast_cancer | PTEN; FGF7; LRP6; MAPK1; SOS2 | 0.014 |
| Cellular_senescence | PTEN; TSC1; HIPK2; HIPK1; MAPK1 | 0.0153 |
| Tuberculosis | ARHGEF12; CAMK2G; RAB5B; MAPK10; MAPK1 | 0.0218 |
| Focal_adhesion | PTEN; MAPK10; ITGB5; MAPK1; SOS2 | 0.0294 |
| Salmonella_infection | RAB5B; MAPK10; MAPK1; SKP1; GCC2 | 0.0332 |
| Human_immunodeficiency_virus_1_infection | TNFRSF1B; WEE1; MAPK10; MAPK1; SKP1 | 0.0332 |
Figure 2Protein–protein interaction analysis representing the interaction networks of miRNA target proteins, depicting two major clusters (PTEN and MAPK1) in the network.